High risk patients are often those who have not been vaccinated, and/or have a number of comorbidities (additional, chronic health problems) such as hypertension, diabetes, hyperlipidemia, depression, and cancer.
Patients already taking multiple drugs to control chronic diseases, could be effected by harmful drug interactions between the their current drugs and Paxlovid. Awareness of potential drug-drug interactions may help to avoid severe adverse drug reactions and improve efficacy of Paxlovid’s anti-COVID-19 activity.
Paxloid contains two medicines in two separate tablets, nirmatrelvir and ritonavir. The drug’s anti-COVID-19 activity relies on the inhibition of SARS-CoV-2 Mpro enzyme activity by nirmatrelvir, which results in inhibition of virus replication. Nirmatrelvir is a substrate of cytochrome P450 CYP3A4 for metabolism.
Ritonavir is an HIV drug that inhibits CYP3A4 and slows the metabolism of Nirmatrelvir, therefore enhancing efficacy of anti-virus activity of Nirmatrelvir.